Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension of APG-20 Study to Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial Lipodystrophy

NCT06679270 is registered in ClinicalTrials.gov with Chiesi Farmaceutici S.p.A. as lead sponsor.

NCT NCT06679270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06679270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension of APG-20 Study to Evaluate the Long-term Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial Lipodystrophy
Lead sponsor
Chiesi Farmaceutici S.p.A.
Phase
Phase 3
Overall status
Recruiting
Start date
October 14, 2024
Completion date
December 31, 2028
Enrollment
24 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

familial partial lipodystrophy